In part one of the SPECTRA clinical trial, 4D-150, an intravitreal gene therapy, demonstrated positive safety outcomes as well as vision gains and central subfield thickness reduction in patients with diabetic macular edema.
“For DME patients, the current treatment paradigm requires time-consuming retinal clinic visits and anti-VEGF injections every 4 to 8 weeks,” Arshad Khanani, MD, MA, FASRS, chair of 4D Molecular Therapeutics’ retina advisory board, told Healio. “This is on top of other regular physician visits needed to control their diabetes. Because of this rigorous schedule, many